Author: Fukuda, Kuniaki; Mori, Kensaku; Hasegawa, Naoyuki; Nasu, Katsuhiro; Ishige, Kazunori; Okamoto, Yoshikazu; Shiigai, Masanari; Abei, Masato; Minami, Manabu; Hyodo, Ichinosuke
Title: Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide. Cord-id: 8w8xbmqk Document date: 2019_1_1
ID: 8w8xbmqk
Snippet: PURPOSE In radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC), it is difficult to assess the ablative margin (AM) precisely by comparing pre- and post-RFA CT images. We prospectively studied the AMs using magnetic resonance imaging (MRI) with pre-administered superparamagnetic iron oxide (SPIO). SPIO is safe for kidney disease patients. MATERIALS AND METHODS Hepatocellular carcinoma patients were treated with RFA within 8 h of SPIO administration. On T2*-weighted MRI performed 4-7
Document: PURPOSE In radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC), it is difficult to assess the ablative margin (AM) precisely by comparing pre- and post-RFA CT images. We prospectively studied the AMs using magnetic resonance imaging (MRI) with pre-administered superparamagnetic iron oxide (SPIO). SPIO is safe for kidney disease patients. MATERIALS AND METHODS Hepatocellular carcinoma patients were treated with RFA within 8 h of SPIO administration. On T2*-weighted MRI performed 4-7 days later, AM was visualized as a hypointense rim. The ablation status was classified as AM(+) if the rim completely surrounded the tumor, AM(0) if the rim was partly discontinuous without tumor protrusion, and AM(-) if the rim was partly discontinuous with tumor protrusion. The minimal thickness of AM was measured. AM(-) tumors were re-treated consecutively. RESULTS In total, 85 HCCs ablated in 76 patients were evaluated. The local recurrence rate at 3 years was 2% for AM(+) tumors and 34% for AM(0) tumors (p < 0.01). In addition, no local recurrence was seen in the tumors with an AM of ≥ 2 mm. CONCLUSION MRI with pre-administered SPIO is useful for determining the AM precisely, and an AM of ≥ 2 mm is recommended for curative RFA. TRIAL REGISTRATION NUMBER This study was registered with UMIN Clinical Trials Registry (UMIN 000025406).
Search related documents:
Co phrase search for related documents- ablative margin and magnetic resonance: 1, 2, 3, 4, 5
- ablative margin and magnetic resonance imaging: 1, 2, 3, 4
- ablative margin assess and local recurrence: 1, 2
- ablative margin assess and magnetic resonance: 1
- ablative margin assess and magnetic resonance imaging: 1
- local recurrence and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9
- local recurrence and magnetic resonance imaging: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date